MX2016008214A - Tratamiento de esclerosis multiple con una combinacion de laquinimod y teriflunomida. - Google Patents
Tratamiento de esclerosis multiple con una combinacion de laquinimod y teriflunomida.Info
- Publication number
- MX2016008214A MX2016008214A MX2016008214A MX2016008214A MX2016008214A MX 2016008214 A MX2016008214 A MX 2016008214A MX 2016008214 A MX2016008214 A MX 2016008214A MX 2016008214 A MX2016008214 A MX 2016008214A MX 2016008214 A MX2016008214 A MX 2016008214A
- Authority
- MX
- Mexico
- Prior art keywords
- teriflunomide
- laquinimod
- combination
- cis
- presenting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona un método de tratamiento a un sujeto aquejado de esclerosis múltiple (EM) o que presenta un síndrome clínicamente aislado (CIS), que comprende administrar laquinimod al sujeto como parte de una terapia de combinación o para usarse directamente en combinación con una dosis superior a la mínima efectiva de teriflunomida. La presente invención también proporciona un paquete y una composición farmacéutica que comprende laquinimod y dosis superior a la mínima efectiva de teriflunomida para tratar un sujeto afligido con EM o que presenta un CIS. La presente invención también proporciona laquinimod para su uso como parte de una terapia de combinación o para usarse directamente en combinación con una dosis superior a la mínima efectiva de teriflunomida en el tratamiento de un sujeto que padece EM o que presenta un CIS. La presente invención proporciona además el uso de laquinimod y dosis superior a la mínima efectiva de teriflunomida en la preparación de una combinación para el tratamiento de un sujeto que padece EM o que presenta un CIS.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361920064P | 2013-12-23 | 2013-12-23 | |
| PCT/US2014/072244 WO2015100365A1 (en) | 2013-12-23 | 2014-12-23 | Treatment of multiple sclerosis with combination of laquinimod and teriflunomide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016008214A true MX2016008214A (es) | 2016-10-14 |
Family
ID=53479671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016008214A MX2016008214A (es) | 2013-12-23 | 2014-12-23 | Tratamiento de esclerosis multiple con una combinacion de laquinimod y teriflunomida. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20160317525A1 (es) |
| EP (1) | EP3086788A1 (es) |
| JP (1) | JP2017501230A (es) |
| AR (1) | AR098924A1 (es) |
| CA (1) | CA2933541A1 (es) |
| HK (1) | HK1227691A1 (es) |
| IL (1) | IL246078A0 (es) |
| MX (1) | MX2016008214A (es) |
| WO (1) | WO2015100365A1 (es) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2214657A1 (en) * | 2007-10-23 | 2010-08-11 | UCB Pharma GmbH | Compounds for treating demyelination conditions |
| AR073295A1 (es) * | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
| US20130197080A1 (en) * | 2010-08-02 | 2013-08-01 | Sanofi | Use of teriflunomide for treating multiple sclerosis |
| EP2766020A4 (en) * | 2011-10-12 | 2015-04-01 | Teva Pharma | TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD |
| TW201347762A (zh) * | 2012-05-02 | 2013-12-01 | Teva Pharma | 高劑量拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於治療多發性硬化症之用途 |
-
2014
- 2014-12-22 AR ARP140104868A patent/AR098924A1/es unknown
- 2014-12-23 WO PCT/US2014/072244 patent/WO2015100365A1/en active Application Filing
- 2014-12-23 EP EP14875012.8A patent/EP3086788A1/en not_active Withdrawn
- 2014-12-23 JP JP2016560885A patent/JP2017501230A/ja active Pending
- 2014-12-23 MX MX2016008214A patent/MX2016008214A/es unknown
- 2014-12-23 CA CA2933541A patent/CA2933541A1/en not_active Abandoned
- 2014-12-23 US US15/107,450 patent/US20160317525A1/en not_active Abandoned
-
2016
- 2016-06-07 IL IL246078A patent/IL246078A0/en unknown
- 2016-12-16 HK HK16114336A patent/HK1227691A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3086788A1 (en) | 2016-11-02 |
| WO2015100365A1 (en) | 2015-07-02 |
| AR098924A1 (es) | 2016-06-22 |
| US20160317525A1 (en) | 2016-11-03 |
| HK1227691A1 (zh) | 2017-10-27 |
| JP2017501230A (ja) | 2017-01-12 |
| CA2933541A1 (en) | 2015-07-02 |
| IL246078A0 (en) | 2016-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014001050A (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero. | |
| MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
| MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| EA201491773A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и диметилфумарата | |
| CA2909335C (en) | Fenfluramine for use in the treatment of dravet syndrome | |
| MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
| SG10201810888XA (en) | Compositions and methods comprising bupropion or related compounds and dextromethorphan | |
| MX2019010601A (es) | Terapia de combinacion para tratar cancer. | |
| MX2019012884A (es) | Terapia de combinacion. | |
| PH12016502355A1 (en) | Pharmaceutical composition | |
| IN2015DN03219A (es) | ||
| EA201691155A1 (ru) | Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств | |
| EA201490378A1 (ru) | ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β | |
| MX2015000485A (es) | Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina. | |
| PH12016502352A1 (en) | Pharmaceutical composition | |
| TW201613578A (en) | Pharmaceutical combinations | |
| MX2015000398A (es) | Formulaciones de laquinimod sin agente alcalinizante. | |
| MX2015010296A (es) | Tratamiento de formas progresivas de esclerosis multiple con laquinimod. | |
| MX2021014120A (es) | Tratamiento de los sintomas asociados a terapia privacion de androgenos. | |
| MY197664A (en) | Immunity enhancing agent for cancer by allergin-1 antagonist | |
| MX2016001177A (es) | Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina. | |
| MX2016008214A (es) | Tratamiento de esclerosis multiple con una combinacion de laquinimod y teriflunomida. | |
| MX2014013491A (es) | Metodos para mantener, tratar o mejorar la funcion cognitiva. | |
| MX2016003763A (es) | Terapia de combinacion con laquinimod para tratamiento de esclerosis multiple. | |
| MX2016001179A (es) | Tratamiento de esclerosis multiple por induccion de alemtuzumab seguido por terapia de laquinimod. |